The landscape for HIV pre-exposure prophylaxis during pregnancy and breastfeeding in Malawi and Zambia: A qualitative study

Autoři: Chifundo Zimba aff001;  Suzanne Maman aff002;  Nora E. Rosenberg aff002;  Wilbroad Mutale aff003;  Oliver Mweemba aff004;  Wezzie Dunda aff001;  Twambilile Phanga aff001;  Kasapo F. Chibwe aff004;  Tulani Matenga aff004;  Kellie Freeborn aff005;  Leah Schrubbe aff005;  Bellington Vwalika aff006;  Benjamin H. Chi aff005
Působiště autorů: UNC Project-Malawi, Tidziwe Center, Lilongwe, Malawi aff001;  Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America aff002;  Department of Health Policy, School of Public Health, University of Zambia, Ridgeway Campus, Lusaka, Zambia aff003;  Department of Health Promotion and Education, School of Public Health, University of Zambia, Ridgeway Campus, Lusaka, Zambia aff004;  Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America aff005;  Department of Obstetrics and Gynecology, School of Medicine, University of Zambia, Ridgeway Campus, Lusaka, Zambia aff006
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article


High HIV incidence rates have been observed among pregnant and breastfeeding women in sub-Saharan Africa. Oral pre-exposure prophylaxis (PrEP) can effectively reduce HIV acquisition in women during these periods; however, understanding of its acceptability and feasibility in antenatal and postpartum populations remains limited. To address this gap, we conducted in-depth interviews with 90 study participants in Malawi and Zambia: 39 HIV-negative pregnant/breastfeeding women, 14 male partners, 19 healthcare workers, and 18 policymakers. Inductive and deductive approaches were used to identify themes related to PrEP. As a public health intervention, PrEP was not well-known among patients and healthcare workers; however, when it was described to participants, most expressed positive views. Concerns about safety and adherence were raised, highlighting two critical areas for community outreach. The feasibility of introducing PrEP into antenatal services was also a concern, especially if introduced within already strained health systems. Support for PrEP varied among policymakers in Malawi and Zambia, reflecting the ongoing policy discussions in their respective countries. Implementing PrEP during the pregnancy and breastfeeding periods will require addressing barriers at the individual, facility, and policy levels. Multi- level approaches should be considered in the design of new PrEP programs for antenatal and postpartum populations.

Klíčová slova:

HIV epidemiology – HIV prevention – Malawi – Pre-exposure prophylaxis – Pregnancy – Zambia


1. Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med. 2014;11(2):e1001608. doi: 10.1371/journal.pmed.1001608 24586123

2. Joint United Nations Programme for HIV/AIDS. Start Free Stay Free AIDS Free: 2019 report. Accessed on August 16, 2019.

3. Chi BH, Rosenberg NE, Mweemba O, Powers KA, Zimba C, Maman S, et al. Involving both parents in HIV prevention during pregnancy and breastfeeding. Bull World Health Organ. 2018;96(1):69–71. Epub 2018/02/07. doi: 10.2471/BLT.17.200139 29403103

4. Joseph Davey D, Farley E, Towriss C, Gomba Y, Bekker LG, Gorbach P, et al. Risk perception and sex behaviour in pregnancy and breastfeeding in high HIV prevalence settings: Programmatic implications for PrEP delivery. PloS one. 2018;13(5):e0197143. Epub 2018/05/15. doi: 10.1371/journal.pone.0197143 29758064

5. Mofenson LM. Risk of HIV Acquisition During Pregnancy and Postpartum: A Call for Action. J Infect Dis. 2018;218(1):1–4. Epub 2018/03/06. doi: 10.1093/infdis/jiy118 29506075.

6. Thomson KA, Baeten JM, Mugo NR, Bekker LG, Celum CL, Heffron R. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Current opinion in HIV and AIDS. 2016;11(1):18–26. Epub 2015/09/30. doi: 10.1097/COH.0000000000000207 26417954

7. Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS (London, England). 2013;27(13):2155–60. Epub 2014/01/05. doi: 10.1097/QAD.0b013e3283629037 24384592

8. Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. Aids. 2017;31(2):213–32. doi: 10.1097/QAD.0000000000001313 27831952.

9. Heffron R, Mugo N, Hong T, Celum C, Marzinke MA, Ngure K, et al. Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention. AIDS (London, England). 2018;32(12):1707–13. Epub 2018/07/13. doi: 10.1097/qad.0000000000001867 30001244

10. Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014;312(4):362–71. doi: 10.1001/jama.2014.8735 25038355.

11. Pintye J, Baeten JM, Celum C, Mugo N, Ngure K, Were E, et al. Maternal Tenofovir Disoproxil Fumarate Use During Pregnancy Is Not Associated With Adverse Perinatal Outcomes Among HIV-infected East African Women: A Prospective Study. J Infect Dis. 2017;216(12):1561–8. Epub 2017/10/19. doi: 10.1093/infdis/jix542 29040666

12. Price JT, Wheeler SB, Stranix-Chibanda L, Hosek SG, Watts DH, Siberry GK, et al. Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa. J Acquir Immune Defic Syndr. 2016;72 Suppl 2:S145–53. doi: 10.1097/QAI.0000000000001063 27355502

13. Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. Journal of acquired immune deficiency syndromes (1999). 2014;66(3):340–8. Epub 2014/05/03. doi: 10.1097/qai.0000000000000172 24784763

14. [UNAIDS] JUNPoHA. Global AIDS Updates. 2016.

15. Health ZMo. Zambia Consolidated Guidelines for Prevention and Treatment of HIV Infection. In: Health Mo, editor. Lusaka2018.

16. Health Mo. Final Copy of Revised National HIV Prevention Strategy. Lilongwe2018.

17. Health MMo. Malawi Integrated Guidelines for Clinical Management of HIV in Children and Adults. In: Unit HA, editor. Lilongwe: Malawi Ministry of Health; 2011.

18. Anonymous. Malawi population-based HIV impact assessment: MPHIA 2015–2016. Accessed on September 8, 2019.

19. Anonymous. Zambia population-based HIV impact assessment: ZAMPHIA 2016. Accessed on September 8, 2019.

20. Reid SE, Dai JY, Wang J, Sichalwe BN, Akpomiemie G, Cowan FM, et al. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr. 2010;53(5):606–13. doi: 10.1097/QAI.0b013e3181bc4869 19838129

21. Keating MA, Hamela G, Miller WC, Moses A, Hoffman IF, Hosseinipour MC. High HIV incidence and sexual behavior change among pregnant women in Lilongwe, Malawi: implications for the risk of HIV acquisition. PLoS One. 2012;7(6):e39109. doi: 10.1371/journal.pone.0039109 22768063

22. Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LA, Yang LP, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS. 1998;12(13):1699–706. doi: 10.1097/00002030-199813000-00019 9764791.

23. Miotti P, Canner J, Chiphangwi J, Liomba G, Saah A, Dallabetta G. Preparations for AIDS vaccine evaluations. Rate of new HIV infection in a cohort of women of childbearing age in Malawi. AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S239–41. Epub 1994/01/01. 7865310.

24. Sandelowski M. Focus on Research Methods. Whatever Happened to Qualitative Description? Research in Nursing & Health, 2000, 23, 334±340. 2000;23:334±40.

25. Sandelowski M. What’s in a Name? Qualitative Description Revisited. Research in nursing & health. 2010;33:77–84.

26. Maxwell JA. Understanding and Validity in Qualitative Research Harvard Educational Review. 1992;62:279–300.

27. WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV, September 2015: World Health Organization; 2015.

28. Davies N, Heffron R. Global and national guidance for the use of pre-exposure prophylaxis during peri-conception, pregnancy and breastfeeding. Sexual health. 2018;15(6):501–12. Epub 2018/11/19. doi: 10.1071/SH18067 30447703.

29. Pintye J, Beima-Sofie KM, Kimemia G, Ngure K, Trinidad SB, Heffron RA, et al. "I Did Not Want to Give Birth to a Child Who has HIV": Experiences Using PrEP During Pregnancy Among HIV-Uninfected Kenyan Women in HIV-Serodiscordant Couples. Journal of acquired immune deficiency syndromes (1999). 2017;76(3):259–65. Epub 2017/08/05. doi: 10.1097/qai.0000000000001516 28777265

30. Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS patient care and STDs. 2015;29(2):102–10. Epub 2014/12/17. doi: 10.1089/apc.2014.0142 25513954

31. Auerbach JD B B, Riordan M. Will and should women in the U.S. use PrEP? Findings from a focus group study of at-risk, HIV-negative women in Oakland, Memphis, San Diego and Washington, D.C. Journal of acquired immune deficiency syndromes (1999). 2012;15:193.

32. Fowler N, Arkell P, Abouyannis M, James C, Roberts L. Attitudes of serodiscordant couples towards antiretroviral-based HIV prevention strategies in Kenya: a qualitative study. Journal of the International AIDS Society. 2014;17(4 Suppl 3):19563. Epub 2014/11/14. doi: 10.7448/IAS.17.4.19563 25394070

33. Fowler N, Arkell P, Abouyannis M, James C, Roberts L. Attitudes of serodiscordant couples towards antiretroviral-based HIV prevention strategies in Kenya: a qualitative study. AIDS patient care and STDs. 2015;29(1):33–42. Epub 2014/11/07. doi: 10.1089/apc.2014.0210 25375792.

34. Krakower DS, Oldenburg CE, Mitty JA, Wilson IB, Kurth AE, Maloney KM, et al. Knowledge, Beliefs and Practices Regarding Antiretroviral Medications for HIV Prevention: Results from a Survey of Healthcare Providers in New England. PloS one. 2015;10(7):e0132398. Epub 2015/07/07. doi: 10.1371/journal.pone.0132398 26146824

35. Govender E, Abdool Karim Q. Understanding women and men’s acceptability of current and new HIV prevention technologies in KwaZulu-Natal, South Africa. AIDS care. 2018;30(10):1311–4. Epub 2018/06/20. doi: 10.1080/09540121.2018.1488027 29914270.

36. Cowan FM, Delany-Moretlwe S, Sanders EJ, Mugo NR, Guedou FA, Alary M, et al. PrEP implementation research in Africa: what is new? J Int AIDS Soc. 2016;19(7(Suppl 6)):21101. Epub 2016/10/21. doi: 10.7448/IAS.19.7.21101 27760680

37. Joint United Nations Programme on HIV/AIDS. Fast-track: ending the AIDS epidemic by 2030. Accessed September 8, 2019. 2014.

38. Pintye J, Drake AL, Kinuthia J, Unger JA, Matemo D, Heffron RA, et al. A Risk Assessment Tool for Identifying Pregnant and Postpartum Women Who May Benefit From Preexposure Prophylaxis. Clin Infect Dis. 2017;64(6):751–8. doi: 10.1093/cid/ciw850 28034882.

39. Caceres CF, Borquez A, Klausner JD, Baggaley R, Beyrer C. Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy. Journal of the International AIDS Society. 2016;19(7(Suppl 6)):21108. Epub 2016/10/21. doi: 10.7448/ias.19.7.21108 27760685

40. Pintye J, Kinuthia J, Roberts DA, Wagner AD, Mugwanya K, Abuna F, et al. Brief Report: Integration of PrEP Services Into Routine Antenatal and Postnatal Care: Experiences From an Implementation Program in Western Kenya. J Acquir Immune Defic Syndr. 2018;79(5):590–5. Epub 2018/09/12. doi: 10.1097/QAI.0000000000001850 30204720.

41. Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, et al. Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda. PLoS Med. 2016;13(8):e1002099. Epub 2016/08/24. doi: 10.1371/journal.pmed.1002099 27552090 interests: Gilead Sciences donated the PrEP medication used in this study. CH received prior funding (05/01/09-04/30/10) for a pharmacokinetics study of TDF in the colon and female genital tract from Gilead Sciences and has a patent pending using a different formulation of the drug used in this study.

42. Claassen C, Mwango L, Lavole M, Gashongore I, Mubanga E, Mumba D, et al. Pre-exposure prophylaxis in Zambia: policy engaegment and initial implementation [Absract WEPEC206]. 22nd International AIDS Conference [Internet]. 2018.

43. Caceres CF, Koechlin F, Goicochea P, Sow PS, O’Reilly KR, Mayer KH, et al. The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention. Journal of the International AIDS Society. 2015;18(4 Suppl 3):19949. Epub 2015/07/23. doi: 10.7448/IAS.18.4.19949 26198341

Článek vyšel v časopise


2019 Číslo 10
Nejčtenější tento týden